Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy

OBJECTIVE: To assess the cost-effectiveness of erlotinib versus supportive care (placebo) overall and within a predefined rash subgroup in elderly patients with advanced non-small-cell lung cancer who are unfit for chemotherapy and receive only active supportive care due to their poor performance st...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Iftekhar, Morris, Stephen, Hackshaw, Allan, Lee, Siow-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499745/
https://www.ncbi.nlm.nih.gov/pubmed/26137881
http://dx.doi.org/10.1136/bmjopen-2014-006733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499745/
https://www.ncbi.nlm.nih.gov/pubmed/26137881
http://dx.doi.org/10.1136/bmjopen-2014-006733

Ejemplares similares